SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 2,498.67 |
| Enterprise Value ($M) | 2,544.73 |
| Book Value ($M) | 169.76 |
| Book Value / Share | 2.78 |
| Price / Book | 14.72 |
| NCAV ($M) | 145.28 |
| NCAV / Share | 2.38 |
| Price / NCAV | 17.20 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.67 |
| Return on Assets (ROA) | -0.53 |
| Return on Equity (ROE) | -0.84 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 5.43 |
| Current Ratio | 5.58 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 308.27 |
| Assets | 332.75 |
| Liabilities | 162.99 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 77.43 |
| Operating Income | -184.36 |
| Net Income | -184.68 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -136.16 |
| Cash from Investing | -5.67 |
| Cash from Financing | 74.37 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | New Enterprise Associates 13 Lp | |||
| 13D/A | Perceptive Advisors Llc | 8.30 | 57.36 | |
| 13G/A | Ra Capital Management, L.p. | 9.00 | -3.37 | |
| 13G/A | Baker Bros. Advisors Lp | 10.80 | 0.69 | |
| 13G | Vanguard Group Inc | 5.46 | ||
| 13G/A | Primecap Management Co/ca/ | 13.63 | 16.52 | |
| 13G/A | Goldman Sachs Group Inc | 8.50 | -3.89 | |
| 13G/A | BlackRock Inc. | 10.70 | 1.38 | |
| 13G/A | State Street Corp | 3.73 | -30.64 | |
| 13G/A | Federated Hermes, Inc. | 4.11 | -62.86 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| ‘ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 96,981 | 576,277 | 16.83 | |
| 57,295 | 243,279 | 23.55 | |
| 127,442 | 491,487 | 25.93 | |
| 110,932 | 275,616 | 40.25 | |
| 59,353 | 148,932 | 39.85 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| RPHM – Reneo Pharmaceuticals, Inc. | RVNC – Revance Therapeutics, Inc. |
| RWOD – Redwoods Acquisition Corp. | SAGE – Sage Therapeutics, Inc. |
| SCYX – SCYNEXIS, Inc. |
Financial data and stock pages provided by
Fintel.io